Innovus Pharmaceuticals Inc (INNV) financial statements (2021 and earlier)

Company profile

Business Address 8845 REHCO ROAD
SAN DIEGO, CA 92121
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 1,2481,56583056733
Cash and cash equivalents 1,2481,56583056733
Receivables 282683483192217
Inventory, net of allowances, customer advances and progress billings 2,3701,726600254266178
Inventory 2,3701,726600254266178
Prepaid expense 1,116363864535535
Deposits current assets      21
Other undisclosed current assets    98  
Total current assets: 5,0163,7222,327544520484
Noncurrent Assets
Property, plant and equipment 2476230355579
Intangible assets, net (including goodwill) 4,8435,2265,8565,8501,4851,295
Goodwill 953953953549429421
Intangible assets, net (excluding goodwill) 3,8904,2734,9035,3011,055874
Deposits noncurrent assets  2115152222
Other undisclosed noncurrent assets 21    233
Total noncurrent assets: 5,1115,3095,9005,9001,5611,629
TOTAL ASSETS: 10,1279,0318,2276,4452,0812,113
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including: 2,6223,4281,463986959 
Accounts payable 1,8452,306647   
Accrued liabilities 237     
Employee-related liabilities  1,118768907907 
Interest and dividends payable  4487953 
Other undisclosed accounts payable and accrued liabilities 540     
Debt 3,3391,305627304314370
Contract with customer, liability108
Other undisclosed current liabilities 1,2844131,9421,440(520)718
Total current liabilities: 7,3535,1464,0312,7297541,088
Noncurrent Liabilities
Long-term debt and lease obligation   552524511
Long-term debt, excluding current maturities   552524511
Liabilities, other than long-term debt 1,437     
Deferred rent credit 181
Business combination, contingent consideration, liability 1,256    
Other undisclosed noncurrent liabilities 1,2282,9823,0484,1371,729572
Total noncurrent liabilities: 2,6652,9823,1024,1621,7531,083
Total liabilities: 10,0188,1287,1336,8912,5072,172
Stockholders' equity
Stockholders' equity attributable to parent, including: 1099031,094(446)(426)148
Common stock 2167122472722
Additional paid in capital 43,96736,37530,10814,94110,7796,531
Accumulated deficit (43,860)(35,640)(29,136)(15,435)(11,232) 
Other undisclosed stockholders' equity attributable to parent      (6,405)
Other undisclosed stockholders' equity      (206)
Total stockholders' equity: 1099031,094(446)(426)(58)
TOTAL LIABILITIES AND EQUITY: 10,1279,0318,2276,4452,0812,113

Income statement (P&L) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues 23,9908,8164,8197361,0307
Revenue, net8,8064,8187316557
Cost of revenue (4,325) (1,270) (395)(2)
Cost of goods and services sold     (292)(2)
Amortization of value of business acquired (voba)   (1,270) (103) 
Gross profit: 19,6658,8163,5497366355
Operating expenses (25,357)(13,916)(10,653)(5,010)(4,815)(3,894)
Other operating income (expense), net
(Other Expenses)
  (7)2(8)  
Other undisclosed operating income  71,2688  
Operating loss: (5,692)(5,099)(5,834)(4,275)(4,180)(3,889)
Nonoperating income (expense) (2,587)(1,402)(7,865)(685) 98
Debt instrument, convertible, beneficial conversion feature      98
Other nonoperating expense (13)(1,402)(7,865)(685)  
Interest and debt expense (1,332)(700)(6,662)(33)(939)(8)
Other undisclosed income from continuing operations before equity method investments, income taxes  7006,66233  
Loss from continuing operations before equity method investments, income taxes: (9,611)(6,501)(13,699)(4,960)(5,119)(3,799)
Other undisclosed income from continuing operations before income taxes 1,332     
Loss from continuing operations before income taxes: (8,279)(6,501)(13,699)(4,960)(5,119)(3,799)
Income tax expense (benefit) (1,965)(3)(2)757  
Loss before gain (loss) on sale of properties: (10,244)(6,504)(13,701)(4,203)(5,119)(3,799)
Other undisclosed net income (loss)     325(158)
Net loss: (10,244)(6,504)(13,701)(4,203)(4,794)(3,956)
Other undisclosed net income (loss) attributable to parent 1,965   (33) 
Net loss available to common stockholders, diluted: (8,279)(6,504)(13,701)(4,203)(4,827)(3,956)

Comprehensive Income ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (10,244)(6,504)(13,701)(4,203)(4,794)(3,956)
Comprehensive loss, net of tax, attributable to parent: (10,244)(6,504)(13,701)(4,203)(4,794)(3,956)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: